Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A consultation with your physician is vital to rule out external factors
Health Canadas approval of Wegovy for chronic weight management in 2022, followed by the 2023 SELECT trial showing a 20% reduction in major adverse cardiovascular events [2], accelerated prescribing in both diabetes and obesity populations
.png)
Lee ChongTAhearnECimminoL
Exclusion criteria involved trials with participants who had a history of diabetes, non-human studies, and studies that did not report relevant outcome measures
2 Materials and methods 2.1 Model overview The United Kingdom Prospective Diabetes Study Outcome Model version 2.1 (UKPDS OM2) is a validated computerized simulation tool for evaluating the long-term effects of interventions and complications in patients with T2DM, as well as economic outcomes ( 2.2 Simulation population and treatment inputs We utilized patient characteristics and treatments from a network meta-analysis comparing once-daily oral semaglutide 14 mg to injectable GLP-1 RAs in individuals with poorly controlled T2DM on basal insulin
